Celldex Therapeutics, Inc. (CLDX)

Celldex Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	34.81	29.43	39.14	43.84	11.23
Short-Term Investments	388.78	275.52	369.11	150.59	53.15
Cash & Cash Equivalents	423.6	304.95	408.25	194.42	64.38
Cash Growth	38.91%	-25.30%	109.98%	201.98%	-31.52%
Receivables	2.63	0.35	0.17	1.8	1.02
Other Current Assets	5.47	12.39	2.42	1.62	1.3
Total Current Assets	431.69	317.69	410.84	197.84	66.7
Property, Plant & Equipment	6.64	7.75	6.52	7.26	7.5
Goodwill and Intangibles	27.19	27.19	27.19	30.69	48.69
Other Long-Term Assets	0.11	0.1	0.1	0.04	0.04
Total Long-Term Assets	33.93	35.04	33.82	38	56.24
Total Assets	465.63	352.74	444.65	235.84	122.93
Accounts Payable	3.49	3.34	1.23	1.05	1.17
Current Debt	1.61	1.45	1.75	1.33	1.94
Other Current Liabilities	26.02	13.83	13.55	11.83	8.53
Total Current Liabilities	31.13	18.61	16.53	14.21	11.64
Long-Term Debt	0.93	2.59	1.3	2.15	1.71
Other Long-Term Liabilities	4.4	5.33	7.35	10.12	15.55
Total Long-Term Liabilities	5.33	7.92	8.65	12.28	17.26
Total Liabilities	36.46	26.53	25.18	26.48	28.91
Total Debt	2.54	4.03	3.04	3.48	3.66
Debt Growth	-36.97%	32.58%	-12.61%	-4.81%	-
Retained Earnings	-1,397.36	-1,255.93	-1,143.61	-1,073.1	-1,013.32
Comprehensive Income	3.31	1.26	1.89	2.59	2.62
Shareholders' Equity	429.17	326.2	419.48	209.36	94.03
Net Cash / Debt	421.06	300.92	405.21	190.94	60.73
Net Cash / Debt Growth	39.92%	-25.74%	112.22%	214.43%	-35.41%
Net Cash Per Share	8.69	6.42	9.45	6.44	4.19
Working Capital	400.57	299.08	394.31	183.64	55.06
Book Value Per Share	8.86	6.96	9.79	7.06	6.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).